| アブストラクト | Aims: We aimed to estimate the resource use and associated costs for patients with peanut allergy (PA) compared to matched controls. Methods: This was a retrospective cohort study using data from the UK Clinical Practice Research Datalink and Hospital Episode Statistics. PA patients were matched to two control cohorts: the first (simple-matched) were matched 1:1 on year of birth, general practice, gender and registration year. The second (atopy-matched) were matched on the same characteristics plus presence/absence of an atopic condition. Prescriptions and primary and secondary care contacts were compared between cases and controls. Results: 15,483 peanut-allergic patients were identified: 13,609 (87.9%) were simple-matched and 9,320 (60.2%) atopy-matched. The total per person annual incremental health-care costs associated with PA were pound253 (atopy-matched) and pound333 (simple-matched). For those with PA and a prior anaphylaxis incremental costs were pound662, for those prescribed an epinephrine autoinjector incremental costs were pound392. Extrapolated to the U.K. population, total excess costs of PA were between pound33 and 44 million in 2015. Conclusions: Patients with PA had increased health-care contacts and consequently increased associated costs compared to controls. Observation bias should be considered in interpretation, but this study suggests that PA presents significant burden to health-care systems. |
|---|
| ジャーナル名 | Expert review of clinical immunology |
|---|
| Pubmed追加日 | 2019/7/16 |
|---|
| 投稿者 | Scott, Laura A; Berni, Thomas R; Berni, Ellen R; De Vries, Jane; Currie, Craig J |
|---|
| 組織名 | a Global Epidemiology, Pharmatelligence , Cardiff , UK.;b Independent consultant to Aimmune Therapeutics Inc ., London , UK.;c The Institute of Population Medicine, School of Medicine, Cardiff University ,;Cardiff , UK. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/31305181/ |
|---|
